Did you know that it is also known as GW610742? What metabolic secrets does this highly anticipated experimental compound hold that make researchers so fascinated by it in studies of fat oxidation and endurance?
What is another name for GW0742
GW0742 capsules (also known as GW610742) is a synthetic, highly selective PPARβ/δ (peroxisome proliferator-activated receptor δ) agonist, originally developed by GlaxoSmithKline (GSK) for research related to metabolism and energy regulation. This compound activates gene pathways involved in fatty acid oxidation, glucose metabolism, energy expenditure, and the regulation of inflammation. It is therefore widely used in research on lipid metabolism, insulin sensitivity, cardiovascular function, and exercise physiology. Animal and cell experiments have shown that it has the potential to promote fat utilization, improve metabolic efficiency, and regulate inflammatory responses; it is primarily used as a research chemical and underground sports nutrition supplement. Researchers are investigating its ability to regulate lipid metabolism, promote fat burning, reduce inflammation, and improve cardiovascular function. It is currently still an experimental research compound. Common synonyms include GW610742, GW-0742, and CAS number 317318-84-6. If you are interested in GW0742, please contact Xi'an Sonwu.
What is GW0742 used for
GW0742 is a synthetic research compound that acts as a highly selective agonist of the nuclear receptor peroxisome proliferator-activated receptor δ (PPARδ). It is primarily used in laboratory and preclinical studies to explore energy metabolism, lipid utilization, endurance, inflammation, and metabolic health.
Researchers typically use GW0742 to:
Study energy metabolism and lipid oxidation: Activation of PPARδ promotes fatty acid oxidation, making the compound an effective tool for studying metabolic regulation and energy balance.
Study athletic performance and endurance: Experimental studies have shown that activating PPARδ can increase the number of oxidized muscle fibers and improve endurance, prompting researchers to explore its effects on skeletal muscle adaptation.
Study metabolic disorders: It has been studied in animal models of obesity, insulin resistance, dyslipidemia, and other metabolic diseases to better understand the role of PPARδ in maintaining metabolic health.
Studying cardiovascular function: Scientists are using the compound to investigate how PPARδ signaling affects vascular health, inflammation, lipid metabolism, and cardiac function.
Studying inflammation and tissue protection: PPARδ activation can modulate inflammatory pathways and cellular stress responses, making GW0742 a valuable tool for studying tissue damage and repair mechanisms.
Currently, the compound shows encouraging biological effects in preclinical studies, with most data derived from cell and animal studies.
How does GW0742 work
It's mechanism of action is through the selective activation of PPARδ, a transcription factor that regulates genes involved in lipid metabolism, energy production, glucose regulation, and inflammation. Through this mechanism, the compound promotes fatty acid oxidation, improves metabolic efficiency, and alters cellular energy utilization.
The Mechanism of Action of GW0742
1. Activation of the PPARδ Receptor
PPARδ is a nuclear receptor found in various tissues, particularly skeletal muscle, liver, adipose tissue, and the heart. Once inside the cell, the compound binds to and activates PPARδ. The activated receptor then interacts with DNA and regulates the expression of various metabolic genes.
2. Promotion of Fatty Acid Oxidation
GW0742 promotes the transcription of genes involved in fatty acid transport and combustion. This shifts cellular energy production towards utilizing stored fat as fuel. Researchers frequently use the compound to study mechanisms related to endurance, weight management, and metabolic flexibility.
3. Improvement of Energy Metabolism
Activation of PPARδ can enhance mitochondrial activity and oxidative capacity in muscle cells. This may enhance the body's ability to utilize fat for energy during prolonged exercise while maintaining glycogen reserves.
4. Affects Glucose Regulation
Experimental studies have shown that PPARδ activation can improve insulin sensitivity and glucose utilization in certain tissues. These effects make it a suitable candidate for studies in models of obesity, diabetes, and metabolic syndrome.
5. May Reduce Inflammatory Signaling
Some preclinical studies have indicated that PPARδ activation can modulate inflammatory pathways. Researchers are exploring whether this mechanism may benefit cardiovascular and metabolic health.
How Long Does GW0742 Stay In Your Body
GW0742 is an experimental PPARδ (peroxisome delta) agonist, primarily studied in laboratory and preclinical studies. Existing preclinical studies indicate that it has a relatively long duration of biological activity compared to some other investigational compounds. In animal models, its elimination half-life has been reported to range from several hours to more than a day, depending on the dose and route of administration. According to general pharmacokinetic principles, a compound is considered substantially eliminated after approximately 5 half-lives. Therefore, if the half-life of it is approximately 12–24 hours, it may remain in the body for 2–5 days or longer, although its biological effects may persist beyond the time the compound itself becomes undetectable.
Distinguishing between detectability and biological activity is also important. Even as blood concentrations decrease, the activation of PPARδ-regulated genes and metabolic pathways may continue for some time, resulting in a duration of drug action exceeding its time in circulation.
If you would like to inquire about the price of the GW0742 capsule or other product information, please get in touch with Xi'an Sonwu directly.
Email: sales@sonwu.com